Literature DB >> 15149350

Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress.

Lara B Pupim1, Jonathan Himmelfarb, Ellen McMonagle, Yu Shyr, T Alp Ikizler.   

Abstract

BACKGROUND: Chronic inflammation and oxidative stress are highly prevalent in patients with chronic kidney disease and end-stage renal disease (ESRD). These conditions contribute to high mortality rates associated with cardiovascular disease, the leading cause of death in this patient population. To our knowledge, no prospective studies have examined how initiation of maintenance hemodialysis (MHD) affects biomarkers of inflammation and oxidative stress status.
METHODS: This was a prospective cohort study evaluating time-dependent changes in C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-10 (IL-10), and protein carbonyl content before and after initiation of MHD over a 12-month period. Fifty incident hemodialysis patients [57.6 +/- 17.2 years, 60% male, 38% Caucasians, 32% insulin-dependent diabetes mellitus (IDDM) were studied, with 50 healthy subjects for comparison. The study variables were assessed before the initial outpatient hemodialysis treatment, and every 3 months thereafter for 12 months.
RESULTS: At baseline, CRP, IL-6, and carbonyl content levels were significantly higher in MHD patients compared with healthy subjects (P < 0.001 for each). After initiation of MHD, there were no significant changes in any of the study variables. Patients who initiated MHD with the highest levels of all the study variables had a significant decrease over the next year, but the variables were still higher than normal at the end of the 12-month study period.
CONCLUSION: Our data show that initiation of MHD does not have significant influence on plasma concentrations of CRP, IL-6, and IL-10, as well as plasma protein carbonyl content. These findings suggest that MHD is ineffective in controlling inflammation and oxidative stress in uremia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15149350     DOI: 10.1111/j.1523-1755.2004.00656.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  34 in total

1.  Effects of combination tocopherols and alpha lipoic acid therapy on oxidative stress and inflammatory biomarkers in chronic kidney disease.

Authors:  Luis F Ramos; Jane Kane; Ellen McMonagle; Phuong Le; Pingsheng Wu; Ayumi Shintani; Talat Alp Ikizler; Jonathan Himmelfarb
Journal:  J Ren Nutr       Date:  2010-12-24       Impact factor: 3.655

2.  Cardiorenal syndrome type 4: a review.

Authors:  Anna Clementi; Grazia Maria Virzì; Ching Yan Goh; Dinna N Cruz; Antonio Granata; Girogio Vescovo; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2013-04       Impact factor: 2.041

3.  Effects of Omega-3 Fatty Acids on Markers of Inflammation in Patients With Chronic Kidney Disease: A Controversial Issue.

Authors:  Chun Hu; Ming Yang; Xuejing Zhu; Peng Gao; Shikun Yang; Yachun Han; Xianghui Chen; Li Xiao; Shuguang Yuan; Fuyou Liu; Yashpal S Kanwar; Lin Sun
Journal:  Ther Apher Dial       Date:  2017-12-22       Impact factor: 1.762

Review 4.  Uremic pericarditis, pericardial effusion, and constrictive pericarditis in end-stage renal disease: Insights and pathophysiology.

Authors:  Karim Abdur Rehman; Jorge Betancor; Bo Xu; Arnav Kumar; Carlos Godoy Rivas; Kimi Sato; Leslie P Wong; Craig R Asher; Allan L Klein
Journal:  Clin Cardiol       Date:  2017-09-05       Impact factor: 2.882

5.  Effects of omega-3 fatty acid plus alpha-tocopherol supplementation on malnutrition-inflammation score, biomarkers of inflammation and oxidative stress in chronic hemodialysis patients.

Authors:  Zatollah Asemi; Alireza Soleimani; Hossein Shakeri; Navid Mazroii; Ahmad Esmaillzadeh
Journal:  Int Urol Nephrol       Date:  2016-08-23       Impact factor: 2.370

6.  Dimethylarginines and inflammation markers in patients with chronic kidney disease undergoing dialysis.

Authors:  Yildiz Oner-Iyidogan; Pernur Oner; Hikmet Kocak; Figen Gurdol; Seldag Bekpinar; Yesim Unlucerci; Yasar Caliskan; Pinar Cetinalp-Demircan; Taner Kocak; Aydin Turkmen
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

7.  Population pharmacodynamic analysis of erythropoiesis in preterm infants for determining the anemia treatment potential of erythropoietin.

Authors:  Mohammad I Saleh; Demet Nalbant; John A Widness; Peter Veng-Pedersen
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-13       Impact factor: 3.619

Review 8.  Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis.

Authors:  Robert A DeAngelis; Edimara S Reis; Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2012-11       Impact factor: 3.144

9.  Fine-tuning of the prediction of mortality in hemodialysis patients by use of cytokine proteomic determination.

Authors:  Stéphanie Badiou; Jean-Paul Cristol; Isabelle Jaussent; Nathalie Terrier; Marion Morena; François Maurice; Hélène Leray-Moragues; Jean-Pierre Rivory; Lofti Chalabi; Cécile Delcourt; Bernard Canaud; Anne-Marie Dupuy
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 8.237

10.  Lipid peroxidation and antioxidant enzymes in children on maintenance dialysis.

Authors:  Danuta Zwołińska; Władysław Grzeszczak; Maria Szczepańska; Katarzyna Kiliś-Pstrusińska; Krystyna Szprynger
Journal:  Pediatr Nephrol       Date:  2006-03-04       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.